Here's a look at some of the latest news regarding ophthalmic drugs and therapies from the past week.
- Earlier today, Imprimis Pharmaceuticals reported positive results for an investigator-initiated clinical study related to the company's triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin (Tri-Moxi-Vanc) Dropless Therapy® formulation that shows statistically significant reduction in cystoid macular edema in patients following cataract surgery.
- Envisia Therapeutics recently announced it had achieved positive three-month interim results for an ongoing 12-month safety and efficacy evaluation of the low dosage form of ENV515 XR (travoprost) — the company's lead product candidate that could offer sustained reduction in intraocular pressure (IOP) for more than six months after a single dose.
- Last week, Aerie Pharmaceuticals, Inc. announced enrollment was complete for its first Phase 3 clinical trial for Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, Mercury 1. And Aerie also reported during its first quarter financial results report that Rocket 4 — the Phase 3 clinical trial for Rhopressa™ designed to provide adequate safety data for approval by European regulatory authorities — remained on schedule for topline 90-day efficacy readout in the fourth quarter of 2016.
- ProtoKinetix, Incorporated announced a paper regarding the company's AAGP™ antifreeze glycopeptide had been submitted for publication in the Journal of Tissue Engineering and Regenerative Medicine had been accepted. AAGP has reportedly demonstrated to significantly improve the viable yield of stem cells transplanted in retinal tissue at the University of British Columbia under the guidance of Dr. Kevin Gregory-Evans, the paper's author.
- Novaliq GmbH recently announced it had enrolled the last patient in its Phase 2 clinical trial for evaluating the safety, efficacy and tolerability of CyclASol® for the treatment of moderate to severe dry eye disease.
- Last week, Acucela Inc. announced it had successfully enrolled the first patient for a Phase 2 clinical trial to assess the benefits of emixustat hydrochloride (emixustat) for the treatment of proliferative diabetic retinopathy (PDR).
- Encore Vision recently reported positive results for its Phase I-II study evaluating the safety and efficacy of EV06 ophthalmic solution 1.5% that targets presbyopia by restoring crystalline lens flexibility.